|
WO2019201866A1
|
|
Fusion protein
|
|
WO2019201868A1
|
|
Coagulation factor based fusion protein with half-life extending polypeptide
|
|
WO2019201855A1
|
|
Lysosomal fusion protein
|
|
WO2019145500A1
|
|
Method of treatment
|
|
BR112020009689A2
|
|
syringe assembly with ion exchange material
|
|
WO2018233895A1
|
|
Fusion protein with half-life extending polypeptide
|
|
AU2018242224A1
|
|
IL-1R-I binding polypeptide
|
|
CA3000060A1
|
|
Modified iduronate 2-sulfatase and production thereof
|
|
BR112018006278A2
|
|
modified lysosomal protein and production thereof
|
|
AU2015248899A1
|
|
Syringe plunger rod
|
|
SG11201608025QA
|
|
Modified sulfamidase and production thereof
|
|
WO2015028558A1
|
|
Stable polypeptides binding to human complement c5
|
|
WO2015144219A1
|
|
Method of treatment
|
|
KR20200105953A
|
|
Polypeptides binding to human complement c5
|
|
MX2013013224A
|
|
Low ph protein purification process.
|
|
BR112013020195A2
|
|
Citrate-free pharmaceutical composition comprising anakinra and use of anakinra
|
|
WO2012078101A1
|
|
Method for the treatment of il-1 mediated diseases
|
|
EP2629789A1
|
|
Method to increase the absorption of unsaturated fatty acids by human infants
|
|
AU2010362576A1
|
|
Method to increase the growth velocity of human infants
|
|
EP1827483A2
|
|
Therapeutic formulations of keratinocyte growth factor
|
